TY  - JOUR
AU  - Brenner, Bluma G
AU  - Thomas, Rejean
AU  - Blanco, Jose Luis
AU  - Ibanescu, Ruxandra-Ilinca
AU  - Oliveira, Maureen
AU  - Mesplede, Thibault
AU  - Golubkov, Olga
AU  - Roger, Michel
AU  - Garcia, Federico
AU  - Martinez, Esteban
AU  - Wainberg, Mark A
PY  - 2016
DO  - 10.1093/jac/dkw071
UR  - http://hdl.handle.net/10668/9956
T2  - The Journal of antimicrobial chemotherapy
AB  - Dolutegravir shows a high barrier to resistance with no previously reported cases of acquired integrase mutations during first-line therapy. In this study, rapid development of the G118R mutation arose following a switch from first-line...
LA  - en
PB  - Oxford University Press
KW  - HIV Integrase Inhibitors
KW  - Heterocyclic Compounds, 3-Ring
KW  - Oxazines
KW  - Piperazines
KW  - Pyridones
KW  - Adult
KW  - Drug Resistance, Viral
KW  - Genotyping Techniques
KW  - HIV Infections
KW  - HIV Integrase
KW  - HIV Integrase Inhibitors
KW  - HIV-1
KW  - Heterocyclic Compounds, 3-Ring
KW  - Humans
KW  - Male
KW  - Microbial Sensitivity Tests
KW  - Middle Aged
KW  - Mutation, Missense
KW  - Oxazines
KW  - Piperazines
KW  - Pyridones
KW  - Treatment Failure
TI  - Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors.
TY  - research article
VL  - 71
ER  -